alexa Multi-epitope Fusion Antigen (MEFA), Novel Technology For Structural Vaccinology
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

16th Euro Global Summit and Expo on Vaccines & Vaccination
June 19-21, 2017 Paris, France

Weiping Zhang, Rahul Nandre and Qiangde Duan
Kansas State University, USA
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560-C1-057
Abstract
Statement of the Problem: Vaccine development often encounters challenge of virulence heterogeneity. Enterotoxigenic Escherichia coli (ETEC) produce immunologically heterogeneous adhesins to attach to host receptors and two distinct enterotoxins to disrupt fluid homeostasis in small intestinal epithelial cells. ETEC bacteria are a leading cause of children’s diarrhea and travelers’ diarrhea. As an ETEC bacterium expressing one type of adhesins and either toxin can cause diarrhea, an effective vaccine must induce protective antibodies against most, if not all, of these adhesins and both toxins. However, conventional approaches are unsuccessful in developing a vaccine to induce broad anti-adhesin and antitoxin antibodies against ETEC diarrhea. Methods & Materials: Aided with computational biology and structural biology, we developed a new structural vaccinology technology called MEFA, multiepitope fusion antigen. By in vitro predicting immunodominant B-cell epitopes from multiple virulence factors, we selected one virulence protein as the backbone and had its surface-exposed but less antigenic epitopes substituted with the most antigenic epitopes from each of the targeting virulence factors for a single immunogen. Applying this MEFA technology, we constructed two MEFAs to include antigenic elements from 7 or 9 ETEC heterogeneous adhesins, examined MEFA immunogenicity in mouse immunization, and assessed protection of MEFA-induced antibodies against ETEC bacterial adherence. Findings: Two ETEC MEFAs, CFA MEFA and adhesin tip MEFA were constructed. The CFA MEFA carries epitopes from the major subunits of 7 most important ETEC adhesins (Fig 1), and the adhesin tip MEFA consists of epitopes from the tip subunits of 9 most prevalent adhesins. Mice immunized with either MEFA developed strong immune responses to each representing adhesin. Moreover, induced antibodies inhibited adherence from these adhesins. Conclusion & Significance: This MEFA technology shows potential for developing broadly protective multivalent vaccines against ETEC diarrhea, and likely against other diseases caused by heterogeneous strains or pathogens.
Biography

Weiping Zhang is a Full Professor in the Diagnostic Medicine/Pathobiology department at Kansas State University. His research mainly focuses on enterotoxigenic Escherichia coli (ETEC) pathogenesis in diarrheal disease and vaccine development against ETEC associated diarrhea. His laboratory has applied the toxoid and toxoid fusion strategies and demonstrated for the first time that non-toxic STa molecules induced neutralizing anti-STa antibodies, and invented the MEFA technology to develop structure-based vaccines against heterogeneous ETEC adhesins.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords